Omnimmune Holdings, Inc. (OMMH) Research

Omnimmune Holdings, Inc. (OMMH), operating through its subsidiary Omnimmune Corp., is a U.S.-based, development-stage biotechnology company. Its core mission involves the integration of various complementary cancer technologies for therapy, diagnosis, and prognosis. The firm holds exclusive rights to a range of monoclonal antibody technologies. Omnimmune aims to craft personalized cancer treatments, employing a combination of active immunization (prophylactic and therapeutic vaccines), passive immunization (monoclonal antibodies), and genomic-based solutions, all designed to target the human chorionic gonadotropin hormone. Following the outcomes of its diagnostic trials, the company intends to commence a Phase I clinical study for its primary therapeutic agent: monoclonal antibodies directed against the beta subunit of human chorionic gonadotropin. Omnimmune Holdings, Inc. is headquartered in Houston, Texas.

Market snapshot

Symbol
OMMH
Price
$0.00
Day change
-0.00%
Market cap
$981.0
P/E ratio
-0.00x
52-week range
0.000099999997-0.0001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Adynxx, Inc. (ADYX)
  • Adhera Therapeutics, Inc. (ATRX)
  • ContraFect Corporation (CFRXQ)
  • DMK Pharmaceuticals Corporation (DMKPQ)
  • eFFECTOR Therapeutics, Inc. (EFTR)
  • Grupo International Inc. (GRPI)
  • IMV Inc. (IMVIF)
  • BioELife Corp. (LITH)

Open Omnimmune Holdings, Inc. (OMMH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.